NCT04438213 - Ertugliflozin in Chronic Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Heart Failure

Interventions

DRUG

Ertugliflozin

Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo

DRUG

Metolazone

Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo

DRUG

Placebo

Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo

Trial Locations (1)

RECRUITING

Yale School of Medicine, New Haven

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER